Rate Video

EHA 2015 | SABRINA trial: Subcutaneous versus intravenous rituximab for follicular lymphoma

Andrew Davies • 12 Jun 2015

EHA 2015

Follicular Lymphoma Antibodies Rituximab

Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses the update of the phase 3 SABRINA trial that was presented at the 20th Congress of the European Hematology Association (EHA). SABRINA evaluated subcutaneous versus intravenous rituximab in patients with previously untreated follicular lymphoma.

Applying molecular understanding of DLBCL to management strategies

Andrew Davies • 15 May 2020

Modifying diagnosis, treatment and research practices in lymphoma as COVID-19 pandemic evolves

Andrew Davies • 15 May 2020

Key therapeutic advances in follicular lymphoma

Andrew Davies • 14 Jun 2017

Mediastinal radiotherapy after chemo for newly diagnosed primary mediastinal lymphoma

Andrew Davies • 19 Jun 2020

Related Videos

The lymphoma tumor microenvironment: therapeutic targeting, genetics, drug optimization

Laura Pasqualucci et al.

Will knowledge of the molecular pathology of lymphoma improve clinical trials?

David Maloney et al.

AUGMENT-ing treatment: lenalidomide plus rituximab for R/R indolent NHL

Oral azacitidine plus R-CHOP for previously untreated NHL